Eliza Slawther is a journalist whose work has appeared in Informa publications. She covers a wide range of topics in the pharmaceutical and healthcare industries, including gene therapy, drug development, regulatory strategies, and healthcare policies. Eliza's articles provide insights into the latest developments and trends shaping the pharmaceutical landscape.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Eliza Slawther's articles predominantly focus on legal policy regulation and government announcements within the healthcare and pharmaceutical industry. Her coverage revolves around institutions such as EMA (European Medicines Agency) and FDA (Food and Drug Administration), with a specific emphasis on drug development, AI regulation, and their impacts.
Given her emphasis on government announcements and regulatory developments in the pharma industry, she would likely be interested in pitches from experts who can provide analysis or commentary about new regulations, policies, or major decisions made by these agencies. Sources well-versed in the workings of EMA, FDA, drug approval processes or AI applications in healthcare are likely to attract her attention.
As Eliza's geographic focus is not specified but given the nature of her coverage related to European agencies like EMA along with global entities like FDA suggests an international outlook for potential stories.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Eliza Slawther
Greater transparency around EU health technology assessment processes “can only be a good thing” for innovative rare disease therapies, Virginie Bros-Facer, the new CEO of the EU network of rare disease patient organizations, EURORDIS, tells the Pink Sheet.
By: Eliza Slawther
The European Commission's proposed reform of the EU pharmaceutical legislation could help improve the number of rare disease therapies available in
By: Eliza Slawther
The European Commission's proposed pharma legislation overhaul could expand the definition of a gene therapy medicinal product, posing challenges both from a regulatory and public perception perspective.
By: Eliza Slawther
More than 90% of companies have submitted new medicines packaging artwork to the UK's drug regulator, the MHRA. The agency urges the remaining marketing authorization holders of its 31 December deadline to comply with the new Windsor Framework arrangements.
By: Eliza Slawther
Pharmaceutical trade associations warn that demand for joint scientific consultations under the incoming EU Health Technology Assessment Regulation will outstrip supply, which could delay market access decisions for innovative therapies.
By: Eliza Slawther
Sponsors of 13 new products, including BridgeBio's acoramidis, soon learn whether or not the European Medicines Agency recommends their drugs for pan-EU marketing approval.
By: Vibha Sharma, Eliza Slawther
The sponsors of nine new medicines that are in the final stages of their review cycle in the EU were due or possibly due to appear before the European Medicines Agency to address outstanding concerns the agency has regarding the marketing applications of their products.
By: Eliza Slawther
The European Medicines Agency has recommended several new products for pan-EU approval, including CSL Behring's drug for hereditary angioedema and BridgeBio's treatment for transthyretin amyloidosis in cardiomyopathy patients.
EU legislators must be “mindful” that any changes made to the EU orphan medicines framework and its incentive structure will impact drugmakers and patients for the next two decades, says Soraya Bekkali, head of Europe, Canada, and international at Alexion.
“Significant progress” has been made in setting up the UK's Rare Therapies Launch Pad pilot scheme, which will construct a “new regulatory pathway tailored specifically for ultra-rare diseases,” a senior scientist involved in the project says.
(833) 317-6278 
